Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Cigna Corp (CI) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Cigna CorpTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Cigna Corp — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Cigna Corp trades at $272.72 (market cap $73.56B). The key difference: Cigna Corp is far larger — about 7.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Cigna Corp pays a 2.24% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOCI
Market Cap
$9.43B$73.56B
Sector
HealthHealth
52-Week High
$356.25$311.00
52-Week Low
$241.71$244.41
Enterprise Value
$9.18B$98.27B
Dividend Yield
2.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.

Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.

Cigna Corp

Cigna (CI) trades at $278.15, showing slight daily weakness but maintaining a strong fundamental profile with consistent earnings beats. The stock appears undervalued with a P/E of 11.51 and P/S of 0.26, while technical indicators show bearish momentum near key support at $271. Recent Q2 2026 results exceeded expectations with EPS of $7.78 versus $7.60 estimates, driving management's raised full-year guidance.

Cigna presents a compelling value opportunity with analyst consensus pointing to 22% upside to the $338.90 price target. However, near-term technical pressure and competitive healthcare margins require monitoring. The company's stable dividend payments and institutional accumulation support long-term confidence despite current bearish technical signals.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Cigna Corp

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.

Read more on CI